Prot #I1F-MC-RHCD: Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate Safety, Tolerability, and Efficacy of Ixekizumab in Patients from 6 to Less than 18 Years of Age with Moderate-to-Severe Plaque Psoriasis

Project: Research project

Project Details

StatusActive
Effective start/end date7/14/176/30/21

Funding

  • Lilly USA, LLC (Prot #I1F-MC-RHCD)